Immune checkpoint inhibitors (ICIs) blocking programmed death-1 (PD-1) (nivolumab and pembrolizumab) or cytotoxic T-lymphocyte antigen-4 (CTLA-4) (ipilimumab) revolutionized the treatment of patients with advanced melanoma (2–4). The gene discussed is PDCD1; the disease is melanoma.